Thomas Gao

Mr. Thomas Gao


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2020 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
MLMijia Lu
Mijia Lu
ZZZijie Zhang
Zijie Zhang
MXMiaoge Xue
Miaoge Xue
BZBoxuan Simen Zhao
Boxuan Simen Zhao
OHOlivia Harder
Olivia Harder
JLJianrong Li
Jianrong Li

11 August 2022 in International Journal of Drug Policy
Verified
Journal Article
Closed access
ALAdam Levin
Adam Levin
PNPaul B Nagib
Paul B Nagib
SDSelina Deiparine
Selina Deiparine
TGThomas Gao
Thomas Gao
JMJustin Mitchell
Justin Mitchell
ADAlan K Davis
Alan K Davis

2 March 2019 in Viruses
Verified
Journal Article
Open access
PDF file
KCKelsey Craig
Kelsey Craig
XDxianjun dai
xianjun dai
JLJianrong Li
Jianrong Li
MLMijia Lu
Mijia Lu
MXMiaoge Xue
Miaoge Xue
JLJianrong Li
Jianrong Li
Human noroviruses (HuNoVs) are responsible for more than 95% of the non-bacterial acute gastroenteritis epidemics in the world. The CDC estimates that every year 21 million individuals suffer from HuNoV-induced gastroenteritis in the United States. Currently, there is no FDA-approved vaccine for HuNoVs. Development of an effective vaccine has been hampered by the lack of an efficient cell culture system for HuNoVs and a suitable small animal model for pathogenesis study. In this study, we developed lactic acid bacteria (LAB) as a vector to deliver HuNoV antigen. A LAB strain (Lactococcus lactis) carrying VP1 gene of a HuNoV GII.4 virus (LAB-VP1) was constructed. It was found that HuNoV VP1 protein was highly expressed by LAB vector and was secreted into media supernatants. To test whether LAB-based HuNoV vaccine candidate is immunogenic, 4-day-old gnotobiotic piglets were orally inoculated with various doses of LAB-VP1. It was found that LABs were persistent in the small intestine of piglets and shed in pig feces for at least 25 days post inoculation. LAB DNA and VP1 were detected in mesenteric lymph nodes and spleen tissue in LAB-VP1 inoculated groups. HuNoV-specific IgG and IgA were detectable in serum and feces respectively at day 13 post-inoculation, and further increased at later time points. After being challenged with HuNoV GII.4 strain, a large amount of HuNoV antigens were observed in the duodenum, jejunum, and ileum sections of the intestine in the LAB control group. In contrast, significantly less, or no, HuNoV antigens were detected in the LAB-VP1 immunized groups. Collectively, these results demonstrate that a LAB-based HuNoV vaccine induces protective immunity in gnotobiotic piglets.

25 January 2022 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
TGThomas Gao
Thomas Gao
XPXueliang Pan
Xueliang Pan
ANAkash Naik
Akash Naik
RKRohan Khandalavala
Rohan Khandalavala
SRStuart Ramsell
Stuart Ramsell
ECEugene Chio
Eugene Chio

11 October 2022 in Case Reports in Otolaryngology
Verified
Journal Article
Open access
PDF file
TGThomas Gao
Thomas Gao
ASAustin Schafer
Austin Schafer
AAAbdulrahman Althubaiti
Abdulrahman Althubaiti
BFBonita Fung
Bonita Fung
CECharles Elmaraghy
Charles Elmaraghy
Lingual leiomyomatous hamartomas are rare lesions of the tongue with largely unknown mechanisms of formation. These lesions are often asymptomatic, though they may present with symptoms, particularly relating to swallow function. Workup should include imaging of the head and neck, and diagnosis should be made histologically. Treatment is surgical excision. This case is a report of a 4-week-old female who presented for evaluation of an asymptomatic 1×1cm dorsal midline tongue mass discovered at birth. The patient was monitored until the age of 9 months, at which time the mass was surgically excised. The patient had an uncomplicated postoperative course. Pathological analysis yielded a diagnosis of leiomyomatous hamartoma.

4 August 2023 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Open access
TGThomas Gao
Thomas Gao
JMJianing Ma
Jianing Ma
DHDaniel Hall
Daniel Hall
XPXueliang Pan
Xueliang Pan
VRVijay K. Rings
Vijay K. Rings
ECEugene G. Chio
Eugene G. Chio
Objectives: The influence of apnea‐ and hypopnea‐predominance on hypoglossal nerve stimulation therapy outcomes (HGNS) is still poorly defined. We assessed the significance of apnea‐ and hypopnea‐predominance in HGNS outcomes.Study Design: Case series with chart review.Setting: Single‐institution tertiary care center.Methods: A total of 216 subjects were included, all of which had undergone drug‐induced sleep endoscopy (DISE) and HGNS implantation. Demographic and polysomnographic data were collected. The 4% apnea‐hypopnea criteria were used to calculate apnea‐hypopnea index (AHI). Central apneas were omitted. Univariate logistic and linear regression were used to study the association between these data and apnea‐predominance and hypopnea‐predominance. Kruskal‐Wallis rank sum test was used to compare medians between groups for DISE collapse patterns.Results: Sixty‐three patients were apnea‐predominant, and 153 patients were hypopnea‐predominant. These 2 groups were similar demographically (p > .20). There was no significant difference in HGNS outcomes between the groups assessed using Sher20 criteria at the 1‐year mark using all‐night, single‐setting polysomnography or home sleep studies. Apnea index (AI)/AHI and reduction in AHI from preoperative to titration were significantly associated (p = .046). The median preoperative hypopnea index was significantly lower (p = .033) in subjects with no oropharyngeal collapse than patients with partial or complete oropharyngeal collapse. There were no significant relationships between AI/AHI and the different degrees of collapse at the velopharynx, oropharynx, tongue base, or epiglottis.Conclusions: In line with CPAP, tonsillectomy, and mandibular advancement therapy studies, we found there was largely no significant difference in DISE anatomy or in HGNS treatment outcomes between apnea‐ and hypopnea‐predominant individuals.